H. Volz

H. Volz, S. Kasper, M. Hatzinger, 2022, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Antidepressant Drug Therapy in the Elderly - A Critical Review of the Controlled Clinical Trials Conducted since 1980

H. Möller, H. Volz, H. Möller, 1994, Pharmacopsychiatry.

Effect of initial treatment with antidepressants as a predictor of outcome after 8 weeks

H. Möller, H. Volz, Y. Sturm, 1995, Psychiatry Research.

Substance P-immunoreactive neurons in the brainstem of the cat related to cardiovascular centers

A. Weindl, H. Volz, M. Reinecke, 2004, Cell and Tissue Research.

Brofaromine in major depressed patients: a controlled clinical trial versus imipramine and open follow-up of up to one year.

H. Möller, H. Volz, 1992, Journal of affective disorders.

[Diagnosis and treatment of anxiety disorders].

H. Volz, 2008, MMW Fortschritte der Medizin.

Subsyndromal generalised anxiety disorder: operationalisation and epidemiology – a systematic literature survey

H. Möller, E. Seifritz, H. Volz, 2021, International journal of psychiatry in clinical practice.

Silexan does not cause withdrawal symptoms even when abruptly discontinued

H. Möller, H. Volz, S. Kasper, 2017, International journal of psychiatry in clinical practice.

Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.

H. Volz, C. Hiemke, S. Härtter, 2007, International journal of clinical pharmacology and therapeutics.

The effects of RS‐8359 on cardiovascular function in healthy subjects and depressed patients

H. Volz, K. Püchler, A. Plenker, 1997, International clinical psychopharmacology.

Monoamine Oxidase Inhibitors

H. Volz, C. Gleiter, 1998 .

Monoamine oxidase inhibitors. A perspective on their use in the elderly.

H. Volz, C. Gleiter, 1998, Drugs & aging.

High-energy phosphates in the frontal lobe correlate with Wisconsin Card Sort Test performance in controls, not in schizophrenics: a 31phosphorus magnetic resonance spectroscopic and neuropsychological investigation

H. Volz, I. Kreitschmann-Andermahr, R. Rzanny, 1998, Schizophrenia Research.

31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients

Stefan Riehemann, Heinrich Sauer, Reinhard Rzanny, 1998, European Archives of Psychiatry and Clinical Neuroscience.

The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression

N. Freemantle, H. Volz, M. Bauer, 2009, European Archives of Psychiatry and Clinical Neuroscience.

Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited

H. Möller, E. Seifritz, H. Volz, 2022, European Archives of Psychiatry and Clinical Neuroscience.

Hypericum and Depression

H. Volz, 2020 .

The relevance of ‘mixed anxiety and depression’ as a diagnostic category in clinical practice

H. Möller, E. Seifritz, H. Volz, 2016, European Archives of Psychiatry and Clinical Neuroscience.

Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression

H. Möller, H. Volz, S. Kasper, 2010, International clinical psychopharmacology.

Continuation and long-term maintenance treatment with Hypericum extract WS® 5570 after recovery from an acute episode of moderate depression — A double-blind, randomized, placebo controlled long-term trial

H. Möller, H. Volz, S. Kasper, 2008, European Neuropsychopharmacology.

Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial

H. Möller, H. Volz, S. Kasper, 2010, International clinical psychopharmacology.

Metabolic mapping using 2D 31P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia

Timm Rosburg, Hans-Peter Volz, Heinrich Sauer, 2007, NeuroImage.

Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: a 31P chemical shift spectroscopic-imaging study

H. Sauer, S. Riehemann, H. Volz, 2000, Biological Psychiatry.

Brofaromine — a review of its pharmacological properties and therapeutic use

H. Möller, H. Volz, C. Gleiter, 2005, Journal of Neural Transmission.

Withdrawal Symptoms and Rebound Syndromes Associated with Switching and Discontinuing Atypical Antipsychotics: Theoretical Background and Practical Recommendations

H. Volz, M. Riedel, A. Cerovecki, 2013, CNS Drugs.

Input dysfunction and beyond—an evaluation of CPT components

H. Volz, H. Sauer, E. Straube, 2002, Schizophrenia Research.

Processing of temporal information and the basal ganglia: new evidence from fMRI

Christian Gaser, Heinrich Sauer, Igor Nenadic, 2003, Experimental Brain Research.

Predictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germany

M. Roca, H. Volz, S. Kasper, 2021, International journal of psychiatry in clinical practice.

Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue.

H. Volz, I. Maurer, P. Schippel, 2009, Bipolar disorders.

Patterns and prevalence of antidepressant drug use in the German state of Baden‐Wuerttemberg: a prescription‐based analysis

H. Volz, O. Junge, C. Gleiter, 2007, Pharmacoepidemiology and drug safety.

Pramipexole as adjunct to haloperidol in schizophrenia Safety and efficacy

H. Volz, S Kasper, A. Heiden, 1996, European Neuropsychopharmacology.

[Cardiovascular irregularities in schizophrenia--more than an epiphenomenon?].

H. Volz, A. Mackert, 1991, Der Nervenarzt.

Rare variants of the gene encoding the potassium chloride co-transporter 3 are associated with bipolar disorder.

C. Freitag, T. Wienker, D. Stephan, 2005, The international journal of neuropsychopharmacology.

Decreased energy demanding processes in the frontal lobes of schizophrenics due to neuroleptics? A 31P-magneto-resonance spectroscopic study

W. Kaiser, H. Sauer, H. Volz, 1997, Psychiatry Research: Neuroimaging.

Phototherapy in nonseasonal depression

H. Volz, R. Stieglitz, A. Mackert, 1991, Biological Psychiatry.

Pooled Analysis of Four Non-Interventional Studies: Effectiveness and Tolerability of the Antidepressant Agomelatine in Daily Practice

H. Volz, G. Hajak, G. Laux, 2017, Advances in Therapy.

Psychopathology: Rating Scales for the Assessment of Mental Status

H. Volz, R. Stieglitz, 2019 .

Brain activation during cognitive stimulation with the Wisconsin Card Sorting Test — a functional MRI study on healthy volunteers and schizophrenics

H. Volz, Christian Gaser, R. Rzanny, 1997, Psychiatry Research: Neuroimaging.

Opipramol for the Treatment of Generalized Anxiety Disorder: A Placebo-Controlled Trial Including an Alprazolam-Treated Group

H. Volz, I. Reimann, H. Möller, 2001, Journal of clinical psychopharmacology.

Antidepressant Drugs and Psychomotor Performance

H. Volz, Y. Sturm, 1995 .

Psychopharmacotherapy of somatoform disorders: effects of opipramol on symptoms of somatization, anxiety, and depression

H. Möller, H. Volz, K. Stoll, 2003, Acta Neuropsychiatrica.

Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited

H. Möller, E. Seifritz, H. Volz, 2022, European Archives of Psychiatry and Clinical Neuroscience.

No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial

H. Möller, E. Seifritz, H. Volz, 2020, The international journal of neuropsychopharmacology.

Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers.

H. Möller, E. Seifritz, H. Volz, 2020, Journal of psychiatric research.

Silexan in anxiety disorders: Clinical data and pharmacological background

H. Möller, H. Volz, S. Kasper, 2018, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine.

H. Möller, H. Volz, S. Kasper, 2014, The international journal of neuropsychopharmacology.

Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities

H. Möller, H. Volz, T. Baghai, 2006, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Cell-mediated Side Effects of Psychopharmacological Treatment

H. Volz, I Maurer, H P Volz, 2001, Arzneimittelforschung.

[Acute paranoid psychotic symptoms after i.m. injection of nandrolone].

H. Volz, I. Teuber, D. Freiwald, 2003, Psychiatrische Praxis.

Brofaromine: Insight into the Nature of Drug Development

H. Möller, H. Volz, C. Gleiter, 1995 .

Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder – evidence from clinical trials

H. Möller, H. Volz, S. Kasper, 2010, Wiener Medizinische Wochenschrift.

Sick leave duration as a potential marker of functionality and disease severity in depression

M. Ladea, H. Volz, L. Bartova, 2022, International journal of psychiatry in clinical practice.

Efficacy of St. John’s wort extract WS® 5570 in acute treatment of mild depression

H. Möller, H. Volz, S. Kasper, 2007, European Archives of Psychiatry and Clinical Neuroscience.

Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set

H. Möller, H. Volz, S. Kasper, 2017, International clinical psychopharmacology.

Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective

H. Volz, A. Altamura, M. Jaeger, 2008, Current medical research and opinion.

Efficacy of Silexan in mixed anxiety–depression – A randomized, placebo-controlled trial

H. Volz, S. Kasper, A. Dienel, 2016, European Neuropsychopharmacology.

Functional magnetic resonance imaging and magnetic resonance spectroscopy in schizophrenia

H. Sauer, H. Volz, 2000 .

Brain activation during cognitive stimulation with the Wisconsin card sorting test—A functional MRI study on healthy volunteers and schizophrenics

H. Sauer, H. Volz, Christian Gaser, 1998, Schizophrenia Research.

Newer and Older Monoamine Oxidase Inhibitors

H. Möller, H. Volz, G. Laux, 1995 .

Increased blink rate in drug-naive acute schizophrenic patients

H. Volz, A. Mackert, C. Woyth, 1990, Biological Psychiatry.

The “DGPPN-Cohort”: a national collaboration initiative by the German Association for Psychiatry and Psychotherapy (DGPPN) for establishing a large-scale cohort of psychiatric patients

Matthias J. Müller, D. Rujescu, M. Rietschel, 2013, European Archives of Psychiatry and Clinical Neuroscience.

Afferent connections of the nucleus centralis amygdalae

H. Volz, M. Knuepfer, G. Stock, 1990, Anatomy and Embryology.

31P-MR spectroscopy in children and adolescents with a familial risk of schizophrenia

W. Kaiser, J. Reichenbach, H. Volz, 2003, European Radiology.

Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials

H. Volz, L. Bartova, S. Kasper, 2023, European Archives of Psychiatry and Clinical Neuroscience.

St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial

H. Möller, H. Volz, S. Kasper, 2003, Psychopharmacology.

Cerebral phosphate metabolism in first-degree relatives of patients with schizophrenia.

W. Kaiser, S. Riehemann, H. Volz, 2001, The American journal of psychiatry.

[Electroconvulsive therapy-induced cardiac decompensation].

H. Volz, M. Linden, 1988, Der Nervenarzt.

Reduced mismatch reaction in male schizophrenics revealed by means of magnetoencephalography (MEG)

H. Sauer, H. Volz, T. Rosburg, 1998, Schizophrenia Research.

Do neuroleptics alter the cerebral intracellular pH value in schizophrenics?—a 31P-MRS study on three different patient groups

H. Sauer, S. Riehemann, H. Volz, 2002, Psychiatry Research: Neuroimaging.

Decreased frontal activation of schizophrenics during stimulation with the continuous performance test—A functional magnetic resonance imaging study

H. Sauer, H. Volz, Christian Gaser, 1998, Schizophrenia Research.

[Antidepressive pharmacotherapy. In slight and severe disease, young and old].

H. Möller, H. Volz, T. Baghai, 2009, Der Internist.

Antidepressive Pharmakotherapie

H. Möller, H. Volz, T. Baghai, 2009, Der Internist.

[Repetitive transcranial magnetic stimulation (rTMS) in the acute and long-term therapy of refractory depression--a case report].

J. Liepert, H. Volz, S. Smesny, 2001, Der Nervenarzt.

Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity

H. Volz, M. Bauer, P. Ninan, 2009, European Archives of Psychiatry and Clinical Neuroscience.

[Therapeutic effects of venlafaxine extended release for patients with depressive and anxiety disorders in the German outpatient setting - results of 2 observational studies including 8500 patients].

H. Volz, I. Anghelescu, W. Dierkes, 2009, Fortschritte der Neurologie Psychiatrie.

Section Review: Central & Peripheral Nervous Systems: MAO-A inhibitors — state of the art

H. Volz, C. Gleiter, 1996 .

[Phosphorus 31 magnetic resonance spectroscopy in schizophrenia research. Pathophysiology of cerebral metabolism of high-energy phosphate and membrane phospholipids].

S. Riehemann, H. Volz, S. Smesny, 2000, Der Nervenarzt.

[Diagnosis and treatment of anxiety disorders].

H. Volz, 2008, MMW, Fortschritte der Medizin.

Psychiatric manifestations of post-COVID-19 syndrome: the potential benefit of Silexan

H. Volz, S. Kasper, A. Eckert, 2023, International journal of psychiatry in clinical practice.

Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia.

H. Möller, H. Volz, S. Bischoff, 2002, European archives of psychiatry and clinical neuroscience.

Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective

H. Volz, M. Jaeger, J. Locklear, 2008, Current medical research and opinion.

Combined measurement of event-related potentials (ERPs) and fMRI.

Monika Sommer, Jörg Meinhardt, H. Volz, 2003, Acta neurobiologiae experimentalis.

Differences in Semantic Information Processing in Schizophrenics

H. Volz, K. Frick, A. Mackert, 1994, Pharmacopsychiatry.

Clinical trials with sigma ligands.

H. Volz, K. Stoll, 2004, Pharmacopsychiatry.

Altered cerebral activation in schizophrenia during individually adjusted task difficulty — evidence from a fMRI study on time perception

H. Volz, Christian Gaser, I. Nenadić, 2000, Schizophrenia Research.